Business
Coloplast A/S - Coloplast revises financial guidance for FY 2025/26 to reflect reduced growth outlook for Kerecis
Announcement no. 04/2026Inside information Coloplast revises the financial guidance on organic growth and EBIT growth in constant currencies before special items for FY 2025/26, reflecting a slower market recovery in the skin substitutes outpatient setting and a resulting lower growth outlook for Kerecis. The Group organic growth is now expected to be 5-6%, from previously around 7%. The EBIT growth in constant currencies before special items is now expected to be around 5%, from previously arou
About this update from Coloplast A/s Class B
[{"type":"image","alt":"Coloplast A/S","displaySize":"","headline":null,"caption":"Coloplast A/S","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":144,"url":"https://media.zenfs.com/en/globenewswire.com/e8ee650caffe7b5e9474eaac1733b4ef"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/CnHAOjRIde9xT5OfHxnjSg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIwMjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/e8ee650caffe7b5e9474eaac1733b4ef","width":300,"height":144}},"lazy":false},{"type":"text","content":"Announcement no. 04/2026Inside information","length":43,"tagName":"p"},{"type":"text","content":"Coloplast revises the financial guidance on organic growth and EBIT growth in constant currencies before special items for FY 2025/26, reflecting a slower market recovery in the skin substitutes outpatient setting and a resulting lower growth outlook for Kerecis. The Group organic growth is now expected to be 5-6%, from previously around 7%. The EBIT growth in constant currencies before special items is now expected to be around 5%, from previously around 7%. Return on invested capital after tax before special items is now expected around 15%.","length":549,"tagName":"p"},{"type":"text","content":"Key financial figures and developments in Q2","length":44,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Group organic growth was 6% in Q2 and EBIT1 growth in constant currencies was 6%.","length":81,"tagName":"p"}]},{"val":[{"type":"text","content":"Organic growth rates by business area: Ostomy Care 7%, Continence Care 8%, Voice & Respiratory Care 8%, Wound & Tissue Repair -2%, and Interventional Urology 8%.","length":169,"tagName":"p"}]},{"val":[{"type":"text","content":"Strong quarter in Chronic Care and Interventional Urology:-Momentum uplift in Ostomy Care as expected following a soft start in Q1, with double-digit growth in the US.-Continued good momentum in Continence Care and Voice & Respiratory Care.-Continued strong momentum in Interventional Urology driven by Men’s Health in the US.","length":333,"tagName":"p"}]},{"val":[{"type":"text","content":"Challenging quarter in Wound & Tissue Repair:-Kerecis at 0% organic growth and 0% EBIT margin before PPA amortisation, reflecting significant sales disruption from the Medicare reimbursement change in the outpatient setting. Growth in the...